Navigation Links
Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
Date:3/16/2009

CHARLOTTE, N.C., March 16 /PRNewswire/ -- Walter Reed Army Medical Center is the latest institution to be added to a number of academic centers involved in a clinical trial that is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) using the Sonablate(R) 500 for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT).

The technology of using HIFU with the Sonablate is a minimally invasive, outpatient procedure that uses a transrectal probe to focus ultrasound energy resulting in a therapeutic rise in heat within the prostate. This results in the focal destruction of prostatic tissue. High Intensity Focused Ultrasound does not use radiation and is non surgical. In a small U.S. safety trial, 91 percent of the participants treated in the study had a negative biopsy at six months.

Some men with prostate cancer who are treated with radiation therapy have a return of their cancer as determined by a rise in their Prostate Specific Antigen (PSA). Many of these men have few alternatives other than hormone therapy. According to the American Cancer Society, possible side effects of hormone therapy include osteoporosis, anemia, loss of muscle mass, depression, and decreased mental acuity.

The principal investigators at Walter Reed Army Medical Center in this study are: MAJ(P) Steven R. Brassell, M.D., and COL David G. McLeod (Ret), M.D., JD.

At this time, eligible participants for the trial must be between the ages of 40 and 80, and have biopsy confirmed local recurrence two or more years following external beam radiation failure. Other selection criteria are applicable for trial entry as well. Patients treated at Walter Reed Army Medical Center must be military beneficiaries.

"We are pleased to announce the addition of Walter Reed as one of our clinical trial sites. Dr. McLeod has been following the progress of HIFU for many years, and we are fortunate to be able to work with him on this important study. We are honored to be able to offer HIFU to the military patient population at Walter Reed and believe that enrollment will occur swiftly at this site," said Steve Puckett, Jr., Chief Executive Officer, USHIFU, the company managing the clinical trials with sponsor Focus Surgery, Inc.

This investigational treatment is usually performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort while urinating. Less common side effects may include urinary stricture, retention, incontinence, impotence and rectal fistula.

For more information about enrolling in HIFU trials, please call: 1-877-874-4389 or visit www.ProstateCancerRecurrentTrial.org.

About USHIFU, LLC

USHIFU, based in Charlotte, NC, is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies

About the Sonablate(R) 500

The Sonablate(R) 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by FSI and is manufactured by Misonix, Inc. (Nasdaq: MSON) who also holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS International distribute the Sonablate(R) 500 in Southeast Asia and the Middle East.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate cancer.


'/>"/>
SOURCE USHIFU
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
2. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
3. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
4. Premier Research Expands its Medical Device Operations to the United States
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
9. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
10. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
11. Foreign Medical Devices are in High Demand in Russia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and their ...
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services has ... announcement was made by Bill Monast , President ... and Nathan Feltman , executives with Home ... Services, LLC. This acquisition helps Hospice ... of technology enabled durable medical equipment (DME) solutions for ...
(Date:2/23/2017)... MELBOURNE, Australia , Feb. 23, 2017 ITL Limited, ... to announce excellent results for the half year ended 31 December ... ITL BioMedical Growth Update" presentation can be viewed here . ... of $2.12m (Dec 2015: $1.04m; up 104%) Earnings ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is ... KLS is a longtime supporter of the event. , "We are pleased that ... said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... (PRWEB) February 23, 2017 ... nation to come together to combine its favorite springtime pastime ... favorite fruit – apples! To celebrate National Nutrition Month, the ... “Apple Madness” bracket tournament – a five-week, five-round online competition ...
(Date:2/23/2017)... MN (PRWEB) , ... February 23, 2017 , ... HealthPostures, ... is sending an expert sit stand solutions representative to the Minneapolis Home and Garden ... Location for the event that is garnering national attention is the Minneapolis Convention Center. ...
Breaking Medicine News(10 mins):